TrialCurve
Home / Trials

JCOG0905: reconstructed Kaplan–Meier curves

Updated 2026-09-25 · reconstructed by TrialCurve from a CC BY-licensed publication

Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.

PublicationJ Clin Oncol. 2025 Mar 26;43(16):1886–97. doi: 10.1200/JCO-24-01281
DOI10.1200/JCO-24-01281
Registry—
Phase—
Conditions—
Interventions—
Sponsor—
Enrolment—
Source licenceFigure published under CC BY 4.0

Disease-free survival — MAP and MAPIF arms

From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: MAP not reached; MAPIF not reached. Survival at 3 years: MAP 64%; MAPIF 64%. Hazard ratio MAP vs MAPIF 0.93 (95% CI 0.49–1.76).

0%20%40%60%80%100%0246810YearsMAPMAPIF
ArmNEventsMedian (Years)
MAP5118not reached
MAPIF5220not reached

Landmark survival (reconstructed)

TimeMAPMAPIF
1 yr74.5%76.6%
2 yr66.6%64.4%
3 yr64.3%64.4%
5 yr64.3%58.9%
7 yr64.3%58.9%
10 yr64.3%—

Checks against the published figure

Download pseudo-IPD (CSV)

Overall survival — MAP and MAPIF arms

From figure panel B · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: MAP not reached; MAPIF not reached. Survival at 3 years: MAP 87%; MAPIF 79%. Hazard ratio MAP vs MAPIF 0.66 (95% CI 0.30–1.44).

0%20%40%60%80%100%0246810YearsMAPMAPIF
ArmNEventsMedian (Years)
MAP5111not reached
MAPIF5215not reached

Landmark survival (reconstructed)

TimeMAPMAPIF
1 yr100.0%98.1%
2 yr95.8%87.8%
3 yr86.6%78.6%
5 yr78.7%70.1%
7 yr74.9%63.1%
10 yr65.6%—

Checks against the published figure

Download pseudo-IPD (CSV)

Disease-free survival (good responders) — Good responders

From figure panel C · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: Good responders not reached. Survival at 3 years: Good responders 75%.

0%20%40%60%80%100%0246810YearsGood responders
ArmNEventsMedian (Years)
Good responders7418not reached

Landmark survival (reconstructed)

TimeGood responders
1 yr94.5%
2 yr82.3%
3 yr74.8%
5 yr70.3%
7 yr70.3%
10 yr70.3%

Download pseudo-IPD (CSV)

Overall survival (good responders) — Good responders

From figure panel C · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: Good responders not reached. Survival at 3 years: Good responders 91%.

0%20%40%60%80%100%0246810YearsGood responders
ArmNEventsMedian (Years)
Good responders747not reached

Landmark survival (reconstructed)

TimeGood responders
1 yr98.6%
2 yr98.6%
3 yr91.5%
5 yr87.5%
7 yr87.5%
10 yr87.5%

Download pseudo-IPD (CSV)

Disease-free survival — Histologic effect grade 1

From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: MAP not reached; MAPIF not reached. Survival at 3 years: MAP 64%; MAPIF 51%. Hazard ratio MAP vs MAPIF 0.73 (95% CI 0.31–1.75).

0%20%40%60%80%100%0246810YearsMAPMAPIF
ArmNEventsMedian (Years)
MAP228not reached
MAPIF3014not reached

Landmark survival (reconstructed)

TimeMAPMAPIF
1 yr68.2%65.8%
2 yr63.6%50.5%
3 yr63.6%50.5%
5 yr63.6%50.5%
7 yr63.6%50.5%
10 yr63.6%—

Download pseudo-IPD (CSV)

Disease-free survival — Histologic effect grade 2

From figure panel B · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: MAPIF not reached; MAP not reached. Survival at 3 years: MAPIF 82%; MAP 65%. Hazard ratio MAPIF vs MAP 0.70 (95% CI 0.25–1.92).

0%20%40%60%80%100%0246810YearsMAPIFMAP
ArmNEventsMedian (Years)
MAPIF226not reached
MAP2910not reached

Landmark survival (reconstructed)

TimeMAPIFMAP
1 yr90.9%75.9%
2 yr81.8%68.8%
3 yr81.8%64.7%
5 yr70.9%64.7%
7 yr70.9%64.7%
10 yr—64.7%

Download pseudo-IPD (CSV)

About these data

Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.

Load these data in R or Python 
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/jcog0905-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)

# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/jcog0905-1.csv")
for arm, g in d.groupby("arm"):
    KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()

Suggested citation: J Clin Oncol. 2025 Mar 26;43(16):1886–97. doi: 10.1200/JCO-24-01281 doi:10.1200/JCO-24-01281. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/jcog0905

Report a problem with these data

Related trials

Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.

Reconstruct a figure Browse all trials